Skip to main content

Cerebrovascular Disease

1
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Innovation Pharmaceuticals
1 program
1
Asprin, CilostazolPhase 31 trial
Active Trials
NCT00333164Completed200Est. Mar 2012
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
PS-3D-DSAN/A1 trial
Active Trials
NCT06769867Not Yet Recruiting134Est. May 2025
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
Asprin, CilostazolPHASE_3

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Innovation PharmaceuticalsAsprin, Cilostazol
UNION therapeuticsPS-3D-DSA

Clinical Trials (2)

Total enrollment: 334 patients across 2 trials

Cilostazol-Aspirin Therapy Against Recurrent Stroke With Intracranial Artery Stenosis

Start: May 2006Est. completion: Mar 2012200 patients
Phase 3Completed

(Withdrawal) AI-Based Low-Dose 3D-DSA Reconstruction

Start: Apr 2025Est. completion: May 2025134 patients
N/ANot Yet Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.